TY9591 vs Osimertinib

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

December, 2024

TY9591 vs Osimertinib

Aug 26, 2024, 21:24 | Blog

Tanja Obradovic: Can we expect new EGFR TKI to surpass osimertinib in primary tumor and intracranial progression of NSCLC

Tanja Obradovic posted on LinkedIn: “Can we expect new EGFR TKI that can significantly surpass…

All: 1 Posts: 1 - 100

'

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

'

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

'

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

'

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

'

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage

ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023